MARINUS PHARMACEUTICALS INC (MRNS) Stock News
NASDAQ:MRNS - Nasdaq - US56854Q2003 - Common Stock - Currency: USD
MRNS Latest News, Press Releases and Analysis
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPY, HEES, MRNS on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates OMIC, MRNS, VCSA on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OMIC, MRNS, VCSA, LBRDA on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40%
Immedica Pharma AB to acquire Marinus Pharmaceuticals, Inc. for $151 million, giving them control of ZTALMY and expanding their global presence.
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
Check out these three micro-cap stocks that show big-time potential upside, but also pose face large obstacles to achieving success.
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Marinus is an under $2 biotech stock with Wall Street analysts price targets ranging from $2 to $13. Its upcoming trial results have big implications.
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024
MRNS stock results show that Marinus Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Marinus Pharma (NASDAQ:MRNS) just reported results for the second quarter of 20...
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
3 Biotech Stocks to Sell in August Before They Crash & Burn
Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains.
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Marinus Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS). Shareholders who purchased...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit Filed by Rosen Law Firm
/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)...
